{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,26]],"date-time":"2026-03-26T17:36:24Z","timestamp":1774546584525,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2009,7,28]],"date-time":"2009-07-28T00:00:00Z","timestamp":1248739200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["J Vet Emergen Crit Care"],"published-print":{"date-parts":[[2009,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p><jats:bold>Objective \u2013<\/jats:bold>To describe the use of IV and oral mycophenolate mofetil (MMF) as adjunctive therapy in 3 dogs with severe generalized myasthenia gravis.<\/jats:p><jats:p><jats:bold>Case Series Summary \u2013<\/jats:bold>Three dogs suffering from severe generalized myasthenia gravis as confirmed by acetylcholine antibody titers were treated with MMF as part of their treatment regimens. All 3 dogs had radiographic evidence of megaesophagus and suffered from severe regurgitation. Each dog was initially treated with pyridostigmine and supportive agents. When clinical remission was not achieved, IV MMF was administered to all dogs. Signs of clinical remission were apparent within 48 hours and all dogs were later maintained on oral MMF following resolution of regurgitation.<\/jats:p><jats:p><jats:bold>New or Unique Information Provided \u2013<\/jats:bold>This is the first report of the use of IV MMF as adjunctive treatment in dogs with severe generalized myasthenia gravis. Outcome was favorable in all 3 dogs and no adverse effects were noted from the MMF.<\/jats:p>","DOI":"10.1111\/j.1476-4431.2009.00433.x","type":"journal-article","created":{"date-parts":[[2009,7,28]],"date-time":"2009-07-28T07:07:01Z","timestamp":1248764821000},"page":"369-374","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":36,"title":["Use of mycophenolate mofetil as a rescue agent in the treatment of severe generalized myasthenia gravis in three dogs"],"prefix":"10.1111","volume":"19","author":[{"given":"Amanda L.","family":"Abelson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Diane","family":"Shelton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan F.","family":"Whelan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lilian","family":"Cornejo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Scott","family":"Shaw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Therese E.","family":"O'Toole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,8,12]]},"reference":[{"key":"e_1_2_7_2_2","volume-title":"Textbook of Veterinary Internal Medicine","author":"Ettinger SJ","year":"2000"},{"issue":"2","key":"e_1_2_7_3_2","first-page":"50","article-title":"Clinical forms of acquired myasthenia gravis in dogs","volume":"11","author":"Dewey CW","year":"1997","journal-title":"25 cases (1988\u20131995)"},{"issue":"1","key":"e_1_2_7_4_2","first-page":"715","article-title":"Acquired canine myasthenia gravis associated with thymoma","volume":"27","author":"Paciello O","year":"2003","journal-title":"histological features and immunohistochemical localization of HLA type II and IgG"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1292\/jvms.64.637"},{"issue":"11","key":"e_1_2_7_6_2","first-page":"1428","article-title":"Risk factors for acquired myasthenia gravis in dogs","volume":"211","author":"Shelton GD","year":"1997","journal-title":"1,154 cases (1991\u20131995)"},{"issue":"6","key":"e_1_2_7_7_2","doi-asserted-by":"crossref","first-page":"830","DOI":"10.2460\/javma.1998.212.06.830","article-title":"Acute fulminating myasthenia gravis in five dogs","volume":"212","author":"King LG","year":"1998","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.65.7.929"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0195-5616(03)00085-8"},{"issue":"11","key":"e_1_2_7_10_2","first-page":"2139","article-title":"Spontaneous remission in canine myasthenia gravis","volume":"57","author":"Shelton GD","year":"2001","journal-title":"implications for assessing human MG therapies"},{"issue":"6","key":"e_1_2_7_11_2","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1111\/j.1939-1676.2006.tb00771.x","article-title":"Management of myasthenia gravis using cyclosporine in 2 dogs","volume":"20","author":"Bexfield NH","year":"2006","journal-title":"J Vet Int Med"},{"issue":"7","key":"e_1_2_7_12_2","doi-asserted-by":"crossref","first-page":"845","DOI":"10.2460\/javma.1984.184.07.845","article-title":"Clinical remission after corticosteroid therapy of acquired myasthenia in three dogs","volume":"184","author":"Maddison JE","year":"1984","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.5326\/15473317-35-5-396"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.5.729"},{"issue":"11","key":"e_1_2_7_15_2","first-page":"837","article-title":"IV immunoglobulin in patients with myasthenia gravis","volume":"68","author":"Zinman L","year":"2007","journal-title":"a randomized controlled trial"},{"issue":"7","key":"e_1_2_7_16_2","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1007\/s004150070149","article-title":"Comparison between double\u2010filtration plasmapheresis and immunoadsorption plasmapheresis in the treatment of patients with myasthenia gravis","volume":"247","author":"Yeh JH","year":"2000","journal-title":"J Neurol"},{"issue":"2","key":"e_1_2_7_17_2","first-page":"S272","article-title":"Mycophenolate mofetil","volume":"80","author":"Danovitch G.","year":"2005","journal-title":"a decade of clinical experience"},{"key":"e_1_2_7_18_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000186389.19911.9c"},{"key":"e_1_2_7_19_2","unstructured":"NielsenL NiessenS RamsayIK et al. The use of mycophenolate mofetil in eight dogs with idiopathic immune mediated haemolytic anaemia. In: Proceedings of the European College of Veterinary Internal Medicine Companion Animal Congress Glasgow Scotland 2005."},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1476-4431.2000.tb00009.x"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-0813.2007.00201.x"},{"issue":"3","key":"e_1_2_7_22_2","first-page":"721","article-title":"Mycophenolate mofetil therapy for acquired myasthenia gravis in dogs","volume":"22","author":"Dewey CW","year":"2008","journal-title":"a comparative retrospective study (1999\u20132007) (abstr.)"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1015828802490"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.tp.0000186390.10150.66"},{"issue":"1","key":"e_1_2_7_25_2","first-page":"97","article-title":"Mycophenolate mofetil for myasthenia gravis","volume":"56","author":"Ciafalone E","year":"2001","journal-title":"an open-label pilot study"},{"issue":"3","key":"e_1_2_7_26_2","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1212\/WNL.51.3.912-a","article-title":"Successful treatment of a patient with severe refractory myasthenia gravis using mycophenolate mofetil","volume":"51","author":"Hauser A","year":"1998","journal-title":"Neurology"},{"key":"e_1_2_7_27_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000094122.88929.0B"},{"key":"e_1_2_7_28_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312374.95186.cc"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000312373.67493.7f"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02233007"},{"issue":"11","key":"e_1_2_7_31_2","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2460\/javma.1997.210.11.1623","article-title":"Intravenous administration of human immune globulin in dogs with immune\u2010mediated hemolytic anemia","volume":"210","author":"Scott\u2010Moncrieff JC","year":"1997","journal-title":"J Am Vet Med Assoc"},{"issue":"4","key":"e_1_2_7_32_2","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1111\/j.1939-1676.2007.tb03010.x","article-title":"Treatment of severe immune\u2010mediated thrombocytopenia with human IV immunoglobulin in 5 dogs","volume":"21","author":"Bianco D","year":"2007","journal-title":"J Vet Intern Med"},{"issue":"6","key":"e_1_2_7_33_2","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.1111\/j.1939-1676.2006.tb00770.x","article-title":"The use of intravenous human immunoglobulin in treatment of severe pemphigus foliaceus in a dog","volume":"20","author":"Rahilly LJ","year":"2006","journal-title":"J Vet Intern Med"},{"key":"e_1_2_7_34_2","first-page":"264","article-title":"IVIG treatment for myasthenia gravis","volume":"1132","author":"Zinman L","year":"2008","journal-title":"effectiveness, limitations, and novel therapeutic strategies"},{"key":"e_1_2_7_35_2","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199601150-00018"},{"key":"e_1_2_7_36_2","unstructured":"Cellcept [package insert]. City State: Roche Laboratories Inc Nutley NJ 1998\u20132008."},{"key":"e_1_2_7_37_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bmt.1705958"},{"issue":"3","key":"e_1_2_7_38_2","first-page":"304","article-title":"Pharmacokinetics of single\u2010dose oral and intravenous mycophenolate mofetil administration in normal dogs (abstr.)","volume":"15","author":"Dewey CW","year":"2001","journal-title":"J Vet Intern Med"}],"container-title":["Journal of Veterinary Emergency and Critical Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1476-4431.2009.00433.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1476-4431.2009.00433.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T13:30:09Z","timestamp":1739280609000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1476-4431.2009.00433.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["10.1111\/j.1476-4431.2009.00433.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1476-4431.2009.00433.x","archive":["Portico"],"relation":{},"ISSN":["1479-3261","1476-4431"],"issn-type":[{"value":"1479-3261","type":"print"},{"value":"1476-4431","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,8]]},"assertion":[{"value":"2009-08-12","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}